Synthesis of (+)-(1S)-1-pyrophosphoryl-(2R, 3R)-2,3-dihydroxy-(4S)-4-(phosphoryloxymethyl)cyclopentane, a stable, optically-active carbocyclic analog of 5-phosphoribosyl-1-pyrophosphate (PRPP)

Tetrahedron

Volumn 53, Issue 21, 1997, Pages 7077-7088

  Parry, Ronald J ^a   Burns, Mark R ^a   Jiralerspong, Sao ^a   Alemany, Lawrence ^a  

^a RICE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PYROPHOSPHORYL 2,3 DIHYDROXY 4 (PHOSPHORYLOXYMETHYL)CYCLOPENTANE; CYCLOPENTANE DERIVATIVE; PYROPHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REACTION ANALYSIS;

EID: 0030905197     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(97)00387-6     Document Type: Article

References (41)

1. Musick, W. D. L. CRC Crit. Rev. Biochem. 1981, 11, 1.
2. Bhatia, M.; Vinitsky, A.; Grubmeyer, C. Biochemistry 1990, 29, 10480-10487.
3. Kanaani, J.; Maltby, D.; Focia, P.; Wang, C. C. Biochemistry 1995, 34, 14987-14996.
4. Gross, J.; Rajavel, M.; Segura, E.; Grubmeyer, C. Biochemistry 1996, 35, 3917-3924.
5. Kim, J. J.; Krahn, J. M.; Tomchick, D. A.; Smith, J. L.; Zalkin, H. J. Biol. Chem. 1996, 271, 15549-15557.
6. Ozturk, D. H.; Dorfman, R. H.; Scapin, G.; Saccettini, J. C.; Grubmeyer, C. Biochemistry 1995, 34, 10764-10770.
7. Smith, J. L.; Zaluzec, E. J.; Wery, J. P.; Niu, L.; Switzer, R. L.; Zalkin, H.; Satow, Y. Science 1994, 264, 1427-1433.
8. Somoza, J. R.; Chin, M. S.; Focia, P. J.; Wang, C. C.; Fletterick, R. J. Biochemistry 1996, 35, 7032-7040.
9. Vasanthakumar, G.; R. L. Davis, J.; Sullivan, M. A.; Donahue, J. P. Gene 1990, 91, 63.
10. S. P. Craig, I.; Yuan, L.; Kuntz, D. A.; McKerrow, J. H.; Wang, C. C. Proc. Natl. Acad. Sci. USA 1991, 88, 2500.
11. Nord, L. D.; Willis, R. C.; Breen, T. S.; Avery, T. L.; Finch, R. A.; Sanghvi, Y. S.; Revankar, G. R.; Robins, R. K. Biochem. Pharmacol. 1989, 38, 3543.
12. (a) Parry, R. J.; Haridas, K. Tetrahedron Lett. 1993, 34, 7013-7016.
13. (b) The racemic alcohol 9a used in the synthesis of racemic 2 was actually a mixture of isomers at the benzylidene position.
14. Kim, J. H.; Wolle, D.; Haridas, K.; Parry, R. J.; Smith, J. L.; Zalkin, H. J. Biol. Chem. 1995, 270, 17394-17399.
15. Recent evidence suggests that the optically active form of 2 may be much more useful for X-ray crystallographic studies than the racemic form: J. L. Smith, personal communication.
16. For reviews of the synthesis of phosphates and pyrophosphates see: (a) Slotin, L.A. Synthesis, 1977, 737-752.
17. (b) Hutchinson, D.W. In Chemistry of Nucleosides and Nucleotides, Vol. 2; Townsend, L.B., Ed.; Plenum Press, New York, 1991, pp. 81-160.
18. (c) Y. Hayakawa, in Comprehensive Organic Synthesis , Vol. 6; Trost, B.M.; Fleming, I., Eds.; Pergamon Press, New York, pp. 601-630.
19. (d) Potter, B.V.L.; Lampe, D. Angew. Chem. Int. Ed. Engl. 1995, 34, 1933-1972.
20. Chittenden, G. J. F.; Regeling, H. Recl. Trav. Chim. Pays-Bas 1986, 105, 186-187.
21. In conjunction with other approaches to enone 6, it was noted that the formation of the benzylidene acetal under equilibrating conditions always leads to a mixture of isomers at the benzylidene carbon atom: Parry, R.J.; Burns, M.R. unpublished results.
22. Borcherding, D.R.; Scholtz, S.A.; Borchardt, R.T. J. Org. Chem. 1987, 52, 5457-5461.
23. (a) Hudlicky, T.; Natchus, M.G.; Nugent, T.C. Syn. Comm. 1992, 21, 151-157.
24. (b) Hill, J.M.; Jenkins, G.N.; Rush, C.P.; Turner, N.J.; Willetts, A.J.; Buss, A.D.; Dawson, M.J.; Rudd, B.A.M. J. Am. Chem. Soc. 1995, 117, 5391-5392.
25. (c) Hill, J.M.; Hutchinson, E.J.; Le Grand, D.M.; Roberts, S.M.; Thorpe, A.J.; Turner, N.J. J. Chem. Soc. Perkin Trans, 1, 1994, 1483-1487.
26. Parry, R.J.; Burns, M.R.; Skae, P.N.; Hoyt, J.C.; Pal, B. Bioorganic Med. Chem. 1996, 4, 1077-1088.
27. Other examples of the photochemical addition of methanol to enones include: (a) Fraser-Reid, B.; Holder, N.L.; Yunker, M.B. J. Chem. Soc. Chem. Comm. 1972, 1286-1287.
28. (b) Guzman, A.; Muchowski, J.M. Tetrahedron Lett. 1975, 2053-2056.
29. (c) Bundy, G.L. Tetrahedron Lett. 1975, 1957-1960.
30. (d) Fraser-Reid, B.; Holder, N.L.; Hicks, D.R.; Walker, D.L. Can. J. Chem. 1977, 55, 3978-3985.
31. Ferguson, D.C.; Gribble, G.W. J. Chem. Soc. Chem. Comm. 1975, 535.
32. Evans, D.A.; Chapman, K.T.; Carreira, E.M. J. Am. Chem. Soc. 1988, 110, 3560-3578.
33. Kierzek, R.; Markiewicz, W.T. Nucleosides and Nucleotides, 1991, 10, 1257-1275.
34. Moffatt, J.G.; Khorana, H.G. J. Am. Chem. Soc. 1961, 83, 649-658.
35. Roseman, S.; Distler, J.J.; Moffatt, J.G.; Khorana. J. Am. Chem. Soc. 1961, 83, 659-663.
36. Jung, A.; Engel, R. J. Org. Chem. 1975, 40, 244-248.
37. (a) Keenan, C.W.; Giesemann, B.W.; Smith, H.A. J. Am. Chem. Soc. 1954, 76, 229-232.
38. (b) Schuetz, R.D.; Caswell, L.R. J. Org. Chem. 1962, 27, 486-489.
39. Kocienski, P.J. Protecting Groups, Thieme, New York, 1994, p. 46.
40. Bochner, B. R.; Maron, D. M.; Ames, B. N. Anal. Biochem. 1981, 117, 81-83.
41. 13C NMR spectrum of optically active 2 was determined on a Bruker DAX-400 spectrometer.